title: Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas.
abstract: Primary effusion lymphomas (PELs) are aggressive Kaposi's sarcoma herpesvirus (KSHV)-induced malignancies with median survival time <6 months post-diagnosis. Mutations in the TP53 gene seldom occur in PELs, suggesting that genetic alterations in the TP53 are not selected during PEL progression. We have reported that p53 reactivation by an inhibitor of the p53-MDM2 interaction, Nutlin-3, induces selective and massive apoptosis in PEL cells leading to efficient anti-tumor activity in a subcutaneous xenograft model for PEL. Here, we show compelling anti-tumor activity of Nutlin-3 in the majority of intraperitoneal PEL xenografts in vivo. Interestingly, our results demonstrate that spontaneous induction of viral lytic replication in tumors could drastically attenuate the p53-dependent apoptotic response to Nutlin-3. Moreover, viral reactivation compromised p53-dependent apoptosis in PEL cells treated with genotoxic anti-cancer agents doxorubicin and etoposide. We have recently demonstrated that the Ser/Thr kinases Pim 1 and 3 are required to trigger induction of the lytic replication cascade of KSHV. We have now assessed the ability of a novel Pim kinase inhibitor to restore the Nutlin-3-induced cytotoxicity in lytic PEL cells. PEL cells induced to lytic replication by phorbol esters showed 50% inhibition of active viral replication following treatment with the Pim kinase inhibitor. Importantly, co-treatment of these cells with the kinase inhibitor and Nutlin-3 resulted in a robust restoration of the Nutlin-3-induced cell death. These results highlight the potential impact of activation of viral lytic replication on disease progression and response to treatment in KSHV-induced lymphomas.
authors.affiliation: Institute of Biotechnology & Research Programs Unit, Genome-Scale-Biology, Biomedicum Helsinki, Institute of Biomedicine, University of Helsinki, Helsinki, Finland.
authors.forename: G
authors.initials: G
authors.lastname: Sarek
authors.forename: L
authors.initials: L
authors.lastname: Ma
authors.forename: J
authors.initials: J
authors.lastname: Enbäck
authors.forename: A
authors.initials: A
authors.lastname: Järviluoma
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: J
authors.initials: J
authors.lastname: Haas
authors.forename: A
authors.initials: A
authors.lastname: Gessain
authors.forename: P J
authors.initials: PJ
authors.lastname: Koskinen
authors.forename: P
authors.initials: P
authors.lastname: Laakkonen
authors.forename: P M
authors.initials: PM
authors.lastname: Ojala
mesh_terms: D017209:Apoptosis; D016158:Genes, p53; D019288:Herpesvirus 8, Human / Q000254:growth & development*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D054685:Lymphoma, Primary Effusion / Q000235:genetics*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D015533:Transcriptional Activation; D014183:Transplantation, Heterologous; D014775:Virus Activation; D014779:Virus Replication
chemical_list: D007093:Imidazoles; D010879:Piperazines; C482205:nutlin 3